Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS ), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS ), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as obstructive sleep apnea (OSA), insomnia, and associated chronic health conditions, today announced compelling clinical data showing that treatment with its FDA‑cleared Vida® oral appliance led to statistically significant improvement in insomnia severity in 100% of study participants, underscoring what the Company believes could be a major new commercial opportunity in the large and underserved global insomnia market.